Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: mannitol; maize starch; pregelatinised potato starch; colloidal anhydrous silica; hypromellose; macrogol 6000; purified talc; titanium dioxide; sodium stearylfumarate - movox (fluvoxamine maleate) is indicated for the treatment of major depression in adults. movox (fluvoxamine maleate) is also indicated for the treatment of obsessive compulsive disorder (ocd) in both children aged 8 years and older, adolescent, and adults.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: pregelatinised potato starch; titanium dioxide; mannitol; maize starch; macrogol 6000; sodium stearylfumarate; purified talc; hypromellose; colloidal anhydrous silica - luvox (fluvoxamine maleate) is indicated for the treatment of: major depression in adults. it is also indicated for the treatment of obsessive compulsive disorder (ocd) in children aged 8 years of age and older, adolescents and adults.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: mannitol; colloidal anhydrous silica; titanium dioxide; pregelatinised potato starch; maize starch; purified talc; macrogol 6000; hypromellose; sodium stearylfumarate - luvox (fluvoxamine maleate) is indicated for the treatment of: major depression in adults. it is also indicated for the treatment of obsessive compulsive disorder (ocd) in children aged 8 years of age and older, adolescents and adults.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 8 mg; aspirin, quantity: 300 mg - tablet, dispersible - excipient ingredients: citric acid; wheat starch; purified talc; saccharin sodium; calcium carbonate; disodium edetate; sodium lauryl sulfate - for the temporary relief of acute moderate pain, inflammation and fever

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 392.3 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - karlor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. karlor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of karlor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ibuprofen, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; titanium dioxide - rheumatoid arthritis, osteoarthritis, juvenile rheumatoid arthritis, primary dysmenorrhoea and pyrexia. brufen is also indicated for the relief of acute and/or chronic pain states in which there is an inflammatory component.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; polysorbate 80 - children and adolescents: zoloft (sertraline hydrochloride) is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd. adults: zoloft (sertraline hydrochloride) is indicated for the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder. zoloft (sertraline hydrochloride) is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse. zoloft (sertraline hydrochloride) is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; sodium starch glycollate; calcium hydrogen phosphate; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; polysorbate 80 - children and adolescents: zoloft (sertraline hydrochloride) is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd. adults: zoloft (sertraline hydrochloride) is indicated for the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder. zoloft (sertraline hydrochloride) is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse. zoloft (sertraline hydrochloride) is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.